Valuation: Processa Pharmaceuticals, Inc.

Market Cap 5.47M 4.73M 4.48M 4.05M 7.61M 524M 7.66M 53.43M 20.55M 266M 20.53M 20.08M 848M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value -71.14K -61.62K -58.27K -52.75K -99K -6.82M -99.75K -695K -268K -3.46M -267K -261K -11.03M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.18%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Processa Pharmaceuticals, Inc.

1 day+4.08%
1 week-9.41%
Current month-4.55%
1 month-19.48%
3 months-11.46%
6 months-33.67%
Current year-32.06%
1 week 1.82
Extreme 1.82
2.12
1 month 1.82
Extreme 1.82
2.43
Current year 1.67
Extreme 1.6701
3.8
1 year 1.67
Extreme 1.6701
14.24
3 years 1.67
Extreme 1.6701
450
5 years 1.67
Extreme 1.6701
4,495.35
10 years 1.67
Extreme 1.6701
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 07/08/2023
Investor Relations Contact 60 28/03/2011
Chief Administrative Officer 61 03/10/2017
Director TitleAgeSince
Chairman 73 28/03/2011
Chairman 60 15/08/2022
Director/Board Member 56 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
08/08/26 Exercice

Chief Executive Officer

3,200 0.1156%
26/07/26 Other

Chief Financial Officer

11,883 0.4293%
26/07/26 Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
+4.08%-9.41%-60.94%-98.98% 5.25M
-1.38%+0.20%+46.42%+96.33% 70.24B
-1.04%-0.81%+34.61%+75.16% 62.63B
-4.29%-3.98%-16.22%+350.66% 27.36B
+1.89%+2.78%+29.51%+15.14% 25.71B
-2.20%-2.00%-1.22%-14.48% 24.83B
+1.61%-0.69%+20.85%-19.42% 19.52B
+1.26%-14.23%+170.04%+298.75% 15.51B
-5.54%+0.69%-8.13%+830.48% 14.69B
-0.26%-4.37%-9.98%+454.22% 14.66B
Average -0.60%-2.85%+20.49%+198.79% 27.52B
Weighted average by Cap. -1.17%-1.32%+30.86%+160.69%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.26M -9.71M -8.79M -16.49M -1.14B -16.62M -116M -44.56M -576M -44.51M -43.53M -1.84B -13.56M -11.75M -11.11M -10.06M -18.88M -1.3B -19.02M -133M -51.01M -660M -50.95M -49.82M -2.1B
Net Debt -1.12M -968K -916K -829K -1.56M -107M -1.57M -10.93M -4.2M -54.37M -4.2M -4.11M -173M -5.54M -4.8M -4.54M -4.11M -7.71M -531M -7.76M -54.12M -20.82M -269M -20.8M -20.34M -859M
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
15/09/26 US$1.957 +4.08% 15,686
14/09/26 US$1.880 -9.62% 26,800
11/09/26 US$2.080 +12.43% 39,353
10/09/26 US$1.850 -7.04% 102,278
09/09/26 US$1.990 -7.87% 25,465

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PCSA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!